CUGBP Elav-like family member 3Genealiases: BRUNOL1 · CAGH4 · ERDA4 · ETR-1 · TNRC4
Q-omics provides the consensus-scored CELF3 profile across patient tissues and cancer cell-line models. CELF3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CELF3 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, CELF3 RNA expression shows 15,163 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRP, and TGCT as cancer lineages where CELF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CELF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CELF3 survival associations across molecular data types. CELF3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CELF3 RNA expression–survival associations across cancer types. High CELF3 expression shows unfavorable associations in MESO, UVM, LIHC, ACC and KIRC, but favorable associations in LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for CELF3 RNA expression.
This table summarizes CELF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CELF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CELF3 shows lower tumor expression in KIRP, KIRC, KICH and COAD and higher tumor expression in LIHC and BRCA. The KIRP box plot shows higher CELF3 RNA expression in normal versus tumor tissue (log2 FC = −0.319, t-test p < 0.001).
This table shows molecular features associated with CELF3 in patient tissues and cancer cell lines. In patient samples, CELF3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CELF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
